2Hidalgo M. Pancreatic cancer[J]. N Engl J Med, 2010, 362 (17) : 1605-1617. DOI:10. 1056/NEJMra0901557.
3Pan S, Wang F, Huang P, et al. The study on newly developed McAb NJO01 specific to non-small cell Lung cancer and itsbiological characteristics[ J]. PLoS One, 2012, 7 ( 3 ) : e33009. DOI: 10. 1371/jaumal. pone. 0033009.
4Duan YF, Li DF, Liu YH, et al. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS [ J 1. Hepatobiliary Pancreatic Dis Int, 2013, 12(2) : 204-209. DOI: 10. 1016/S1499-3872( 13 )60032-6.
5Yoo T, Lee WJ, Woo SM, et al. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer[J]. Int J Radiat Oncol Biol Phys,2011,81 (4) : 623-630. DOI: 10. 1016/j. ijrobp. 2011. 02. 063.
6Ochi Y, Okabe H, Inui T, et al. Tumor marker-present and future[J]. Rinsho Byori, 1997, 45(9) : 875-883.
